Drug Profiles mentioned in this report are afatinib dimaleate, alisertib, AXL-1717, bevacizumab, CC-122, CDX-1401, Dendritic Cell Therapy for Gliomas, Dendritic Cell Therapy for Oncology, DNX-2401, ETS-2101, galunisertib, mibefradil
dihydrochloride, nilotinib, palbociclib, panobinostat, pelareorep, plerixafor, Stem Cell Therapy for Glioma, temsirolimus and vocimagene amiretrorepvec + flucytosine ER.
ketoconazole, clarithromycin, ritonavir, voriconazole, mibefradil
lacidipine, lercanidipine, manidipine, mibefradil
Sildenafilin klirensini uzatan ilaglar Amiodarone Cerivasatin Atorvastatin Disopyramide Digitoxin Simvastatin Losartan Quinidine Felodidine Verapamil Lovastatin Mibefradil
Diltiazem Isradipine Nifedipine
Their study found that mibefradil
had the same effect as the dihydropyridines in lowering blood pressure, yet with lower fluid filtration, suggesting that mibefradil
is not as harmful to vascular permeability in hypertensive rats as dihydropyridines.
The Prescription Drug User Fee Act and FDAMA provisions have had positive effects on accelerated development and expanded access, but several drugs were withdrawn from the market after the new laws (eg, mibefradil
, dexfenfluramine, terfenadine, bromfenac, and troglitazone) and debate ensued.
(Posicor), a potent inhibitor of CYP3A4, was withdrawn from the market after numerous reports of serious drug-drug interactions.
Made from the drug mibefradil
, the hexagonal tablets belong to a relatively new class of drug called calcium channel blockers.
The 30-patient dose escalation trial evaluated the detailed pharmacokinetics of mibefradil
administered four times a day and confirmed its safe dose levels for use in a Phase 1b trial.
Concomitant therapy with the tetralol-class calcium channel blocker mibefradil
(see PRECAUTIONS, Drug Interactions).
The Phase 1b trial is a dose escalation trial of Interlaced Therapy[TM] -- using Tau's first product candidate mibefradil
sequentially administered with a cytotoxic drug -- in patients with recurrent high-grade glioma.
Tau Therapeutics is repositioning former hypertension drug, mibefradil
dihydrochloride, in its Interlaced Therapy[TM] method to treat solid tumor cancers.